

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 November 2002 (14.11.2002)

(10) International Publication Number
WO 02/089739 A2

(51) International Patent Classification⁷:

A61K

(74) Agents: KONSKI, Antoinette, F. McCutchen Doyle Brown & Enersen LLP et al.; Three Embarcadero Center, Suite 1800, San Francisco, CA, 94111-4067 (US).

(21) International Application Number: PCT/US02/14500

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 9 May 2002 (09.05.2002)

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/290,099

9 May 2001 (09.05.2001) US


(71) Applicant (*for all designated States except US*): NEWBIO-
TICS, INC. [US/US]; 4939 Directors Place, San Diego,
CA 92121-3829 (US).

Published:

— without international search report and to be republished upon receipt of that report

[Continued on next page]

(54) Title: PEPTIDE DEFORMYLASE ACTIVATED PRODRUGS



(57) Abstract: This invention provides a method for inhibiting the growth of a microorganism that expresses Peptide Deformylase by contacting the microorganism with an effective amount of the compound described herein. This method inhibits the growth of gram-positive and gram-negative microorganisms, e.g., *S. aureus*, *S. epidermidis*, *K. pneumoniae*, *E. aerogenes*, *E. cloacae*, *M. Catarrhalis*, *E. coli*, *E. faecalis*, *H. influenzae* and *P. aeruginosa*. This method can be practiced in vitro, ex vivo and in vivo. Further provided is a method for alleviating the symptoms of an infection by a Peptide Deformylase expressing microorganism in a subject by administering or delivering to the subject an effective amount of the compound described above.

WO 02/089739 A2

BEST AVAILABLE COPY

WO 02/089739 A2



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

PEPTIDE DEFORMYLASE ACTIVATED PRODRUGS

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit under 35 U.S.C. § 119(e) to U.S. Provisional
5 Application Serial No. 60/290,099, filed May 9, 2001, the content of which is hereby
incorporated by reference into the present disclosure.

TECHNICAL FIELD

The present invention relates to the field of Enzyme Catalyzed Therapeutic
10 Activation (ECTA™) therapy and in particular, ECTA therapies specific for
microorganisms that express Peptide Deformylase (“PDF”).

BACKGROUND

Throughout this disclosure, various publications are referenced by first author
15 and date, within parentheses, patent number or publication number. The complete
bibliographic reference is given at the end of the application. The disclosures of these
references are hereby incorporated by reference into this disclosure to more fully
describe the state of the art to which this application pertains.

Enzyme Catalyzed Therapeutic Activation (ECTA™) therapy is a novel
20 technology that provides unique prodrug substrates for target enzymes. Unlike
conventional therapies, ECTA prodrugs neither inhibit nor irreversibly inactivate the
target enzyme. U.S. Patent Nos. 6,159,706; 6,245,750 and 6,339,151B1. See also
PCT/US98/16607; PCT/US99/01332; and PCT/US00/20008.

Target enzymes convert the ECTA prodrug into a toxin preferentially within the
25 target cell or in an environment wherein the target enzyme is expressed as compared to
an environment where it is absent, as in an infected cell. Because the compounds do not
require a targeting agent, they can be directly utilized, topically or systemically.

ECTA molecules do not, in most instances, yield cytotoxic products spontaneously (without target enzyme activation). They are not appreciably activated by non-targeted enzymes, as this may result in toxicity to non-diseased or non-infected tissue. Table 1 summarizes the characteristics of ECTA molecules and enzyme activators.

Table 1

Characteristics of ECTA Target Enzymes	Characteristics of ECTA Prodrugs
Infectious Disease: Must be present only in target cells (including diseased cells, bacteria, fungi, etc.). The enzyme should be necessary for continued viability or pathogenicity.	Must be able to get into cells (by itself or as prodrug).
Must process a molecule that resembles the natural substrate (an ECTA molecule) into cytotoxic species. The resemblance only has to be significant with respect to the specificity of the enzyme/substrate interaction and the ability of the enzyme to process the substrate intracellularly into toxic species.	At least one of the products formed from the enzymatic reaction must be cytotoxic. However, the ECTA remain in inactive form until activated by the target enzyme. The compound must have a high degree of specificity for the targeted enzyme, although conversion by a non-targeted enzyme is acceptable if the product(s) are not cytotoxic.
Must not be inactivated by the ECTA molecule, intermediate(s), or the product(s) of the reaction.	Must not inhibit or deactivate the targeted enzyme.

In cases of bacterial, viral and fungal infections in plants, people or agriculturally important animals, metabolic pathways being present in the pathogenic organisms, but absent in the host are a source of potential ECTA target enzymes. For example, some pathways, as well as the enzymes involved, have only been found in bacteria, fungi and plants and not in mammalian cells. One example is the synthesis of "essential" amino acids - amino acids that animals cannot synthesize and must ingest with food. Nelson and Cox (1972).

Another example is Peptide Deformylase ("PDF", EC 3.5.1.31) which catalyses deformylation of N-terminal N-formyl methionine in a growing polypeptide chain. Meinnel (1999). The enzyme is present and active in bacteria (Meinnel et al, 1993), but has not been reported to be present in mammalian cells. Sequences homologous to bacterial PDF sequences have been recently found in mammals but their exact function is unknown. Giglione (2000a) and (2000b).

Because the enzyme is not active in humans it has been used as a target for antibacterial drugs, mostly PDF inhibitors. Dithiols can act as non-specific PDF inhibitors by coordination of sulphydryl groups with the active site metal ion. Rajagopalan (1997). In case of 1,2- or 1,3- dithiols a slow extraction of the metal ion from the active site takes place. The formation of stable 5- or 6-membered rings, respectively, each containing two metal-sulfur bonds, accounts for this effect.

A rationally designed combinatorial library was used to select mechanism-based PDF inhibitors of the general structure HS-CH₂-CH(R_a)-CONH-CH(R_b)-CONH-R_c. Wei et al. (2000a). The optimal inhibitor selected from the library possesses an n-Bu group as an R_a, R_b = -(CH₂)₃-NH-C(=NH)-NH₂, and R_c is 2-naphthalene. This compound acts as a competitive PDF inhibitor with a K_i of 15 nM.

Jayasekera et al. (2000) describes a series of non-peptidic compounds structurally related to the known anticholesteremic thyropropic acid to inhibit *E. coli* PDF. Actinonin is reported to be a potent PDF inhibitor with activity in the subnanomolar K_i range. Chen (2000).


Wei, et al. (2000a) describe that 5'-dipeptidyl derivatives of 5-fluorodeoxyuridine release a small molecule (5-fluorodeoxyuridine (5-F-dUrd)) upon PDF catalyzed deformylation. 5-F-dUrd formation was monitored in the reaction of the substrate catalyzed by purified PDF or *E. coli* crude lysates. The compound was marginally cytotoxic (IC₅₀ > 100 μM) when applied to *E. coli* bacteria. Potency was not increased by increased expression of PDF in bacteria (using a PDF-overexpressing strain). The compound was slightly more effective (IC₅₀ = 50 μM) against gram-positive microorganisms.

Additional inhibitors are described in Apfel et al. (2000), Apfel et al. (2001a), Apfel et al. (2001b), Clements et al. (2001), Durand et al. (1999), and Chen et al. (2000).

However, a compound or agent that is not an inhibitor but rather selectively and effectively activated by PDF to a toxin has not been described. This invention satisfies this need and provides related advantages as well.

DISCLOSURE OF THE INVENTION

This invention provides a prodrug compound having the structure:



5

wherein R_1 , R_2 , R_4 , and R_5 are independently the same or different and are selected from the group consisting of hydrogen, a substituted or unsubstituted C_5 - C_{14} aryl group and a substituted or unsubstituted, saturated or unsaturated C_1 - C_6 alkyl group;

10 wherein R_3 is selected from the group consisting of a substituted or unsubstituted aryl group and a substituted or unsubstituted, saturated or unsaturated C_1 - C_6 alkyl group and $-CH_2-CH_2-X-CH_3$, wherein X is selected from the group consisting of $-O-$, $-S-$, $-NH-$, $-NR_6-$, and $-CH_2-$; where R_6 is a lower alkyl;

15 wherein A_1 and A_3 are independently the same or different and are selected from the group consisting of $=O$, $=S$, $=NH$, $=N-OH$, or $=N-R_7$, where R_7 is hydrogen or a C_1 - C_6 alkyl;

20 wherein A_2 is absent or selected from the group consisting of $=O$, $=S$, $=NH$, $=N-OH$, $=N-R_8$, or $-C(R_9)(R_{10})-$, wherein R_8 , R_9 , and R_{10} are independently the same or different and are selected from the group consisting of hydrogen or a C_1 - C_6 alkyl;

25 wherein B_1 is selected from the group consisting of $-O-$, $-S-$, $-NH-$ or $N(R_{11})-$, wherein R_{11} is selected from the group consisting of hydrogen and a C_1 - C_6 alkyl;

wherein B_2 is absent or is selected from the group consisting of $-O-$, $-S-$, $-N(R_{12})-$, or $-C(R_{13})(R_{14})-$, where R_{12} , R_{13} , and R_{14} are independently the same or different and are selected from the group consisting of hydrogen or a substituted or unsubstituted, saturated or unsaturated alkyl;

wherein the fragment $-B_2-C(R_4)(R_5)-C(=A_3)-$ in its entirety is a naturally occurring amino acid such as proline, a derivative or analog thereof, or a


peptidomimetic thereof;

wherein the fragment -B₂-C(R₄)(R₅)-C(=A₃) - in its entirety is proline, a derivative or analog thereof, or a peptidomimetic thereof;

wherein B₃ is absent or is selected from the group consisting of -O-, -S-, or
5 -NH-, or -N(R₁₅)-, wherein R₁₅ is selected from the group consisting of hydrogen and
a C₁-C₆ alkyl;

wherein B₄ is absent or is selected from the group consisting of -O-, -S-, -
10 N(R₆)-, and -C(R₁₆)(R₁₇)- and wherein R₁₆ and R₁₇ are independently the same or
different and are selected from the group consisting of hydrogen or a substituted or
unsubstituted, saturated or unsaturated alkyl;

wherein a linker is absent or is a traceless linker is selected from the group
consisting of, but not limited to, -C₆H₄-CH₂- and -C₆H₄-CH₂-X₁-C(=X₂)- wherein X₁
and X₂ are independently the same or different are selected from the group consisting of
-O-, -S- and -N(R_a) where R_a is -hydrogen or a lower alkyl, and -(CH₂)_n-NR_b-
15 (C=O)- which has the structure:



wherein n = 2 or 3 and R_b is hydrogen or a lower alkyl;

20 and wherein a toxin is intended to include any agent that is toxic to a cell upon
release by an "activating" enzyme, with the proviso that the toxin is not 5-
fluorodeoxyuridine (5-F-dUrd).

In one aspect, the compound is as noted above but that R₁ and R₂ are both
hydrogen.

25 In a further aspect, the compound is as noted above but that R₃ is -CH₂-CH₂-X-
CH₃, wherein X is selected from the group consisting of oxygen, sulfur or methylene.
In a yet further aspect, the compound is as noted above but that X is sulfur.

In one aspect, the compound is as noted above but that A₁ and A₂ are both
oxygen.

In a further aspect, the compound is as noted above but that B₁ is -NH-.

In a further aspect, the compound is as noted above but that B₄ is absent.

In a further aspect, the toxin is selected from the group consisting of 2-mercaptopuridine-N-oxide, ciprofloxacin, norfloxacin, and nitrogen mustard, and the 5 derivatives and analogues thereof.

In one aspect, the compound is as noted above but that B₂ is -NH, B₃ is -O-, R₄ is 2-methyl-propyl and R₅ is hydrogen.

In one aspect, the compound is as noted above but that R₄ is 2-methyl-propyl and R₅ is hydrogen.

10 Also provided by this invention is a method for inhibiting the growth of a microorganism that expresses PDF by contacting the microorganism with an effective amount of the compound as described above. This method inhibits the growth of gram-positive and gram-negative microorganism, e.g., of *S. aureus*, *S. epidermidis*, *K. pneumoniae*, *E. aerogenes*, *E. cloacae*, *M. catarrhalis*, *E. coli*, *E. faecalis*, *H. influenzae* and *P. aeruginosa*. This method can be practiced *in vitro*, *ex vivo* and *in vivo*. Further provided is a method for alleviating the symptoms of an infection by a PDF expressing microorganism in a subject by administering or delivering to the subject an effective amount of the compound described above. A "subject" is defined herein and includes mammals such as human patients.

20 This invention also provides a composition comprising the prodrug compounds as described above, alone or in combination with other compounds or other agents, known or yet to be discovered, and a carrier. In one aspect, the carrier is another molecule or an inert substance such as a plate or column. In an alternative embodiment, the carrier is a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers are known in the art and described briefly above.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 is a proposed reaction scheme for PDF activation of the compounds of this invention.

30 Figure 2 shows dependence of the rate of NB3068 reaction catalyzed by purified PDF on NB3068 concentration.

Figure 3 shows time dependence of the concentration of NB3068 in the reaction catalyzed by different concentrations of purified PDF.

Figure 4 shows dependence of the initial rate of the NB3068 reaction catalyzed by purified PDF on PDF concentration.

5 Figure 5 shows time dependence of the concentration of NB3068 in the reaction catalyzed by purified PDF at different concentrations of actinonin.

MODES FOR CARRYING OUT THE INVENTION

The practice of the present invention will employ, unless otherwise indicated,
10 conventional techniques of organic chemistry, pharmacology, molecular biology
(including recombinant techniques), cell biology, biochemistry, and immunology, which
are within the skill of the art. Such techniques are explained fully in the literature, such
as, "MOLECULAR CLONING: A LABORATORY MANUAL" Second Edition (Sambrook et al.,
1989); "OLIGONUCLEOTIDE SYNTHESIS" (M.J. Gait, ed., 1984); "ANIMAL CELL CULTURE"
15 (R.I. Freshney, ed., 1987); the series "METHODS IN ENZYMOLOGY" (Academic Press,
Inc.); "HANDBOOK OF EXPERIMENTAL IMMUNOLOGY" (D.M. Weir & C.C. Blackwell,
eds.); "GENE TRANSFER VECTORS FOR MAMMALIAN CELLS" (J.M. Miller & M.P. Calos,
eds., 1987); "CURRENT PROTOCOLS IN MOLECULAR BIOLOGY" (F.M. Ausubel et al., eds.,
1987, and periodic updates); "PCR: THE POLYMERASE CHAIN REACTION" (Mullis et al.,
20 eds., 1994); "CURRENT PROTOCOLS IN IMMUNOLOGY" (J.E. Coligan et al., eds., 1991); J.
March, ADVANCED ORGANIC CHEMISTRY: REACTIONS, MECHANISMS AND STRUCTURE,
4th edition (John Wiley & Sons, NY (1992)).

As used herein, certain terms may have the following defined meanings.

The singular form "a," "an" and "the" include plural references unless the
25 context clearly dictates otherwise. For example, the term "a cell" includes a plurality of
cells, including mixtures thereof.

The term "comprising" is intended to mean that the compositions and methods
include the recited elements, but not excluding others. "Consisting essentially of" when
used to define compositions and methods, shall mean excluding other elements of any
30 essential significance to the combination. Thus, a composition consisting essentially of
the elements as defined herein would not exclude trace contaminants from the isolation

and purification method and pharmaceutically acceptable carriers, such as phosphate buffered saline, preservatives, and the like. "Consisting of" shall mean excluding more than trace elements of other ingredients and substantial method steps for administering the compositions of this invention. Embodiments defined by each of these transition 5 terms are within the scope of this invention.

As used herein, the term "peptidomimetic" refers to a compound containing non-peptidic structural elements that is capable of mimicking or antagonizing the biological action(s) of a natural parent peptide.

As used herein, the term "substituents" includes, but is not limited to halogen 10 atoms and halomethyl groups such as CF₃ and CCl₃; oxygen containing groups such as oxo, hydroxy, carboxy, carboxyalkyl, alkoxy, alkoyl, alkoyloxy, aryloxy, aryloyl, and aryloyloxy; nitrogen containing groups such as amino, alkylamino, dialkylamino, cyano, azide and nitro; sulfur containing groups such as thiol, alkylthiol, sulfonyl and sulfoxide; heterocyclic groups which may themselves be substituted; alkyl groups which 15 may themselves be substituted; and aryl groups which may themselves be substituted.

The term "alkyl" refers to any branched or unbranched, cyclic or acyclic, saturated (alkyl) or unsaturated (alkaryl, alkenyl or alkynyl) hydrocarbyl radical. This term is not limited to a monovalent radical. Where cyclic, the alkyl group is C₃ to C₁₂. Where acyclic, the alkyl group is C₁ to C₁₆. The term "alkoxy" and "aryloxy" means 20 alkyl-O and aryl-O groups, respectively. Reference to "alkoyl" and "aryloyl" groups means alkyl-CO and aryl-CO, respectively.

The term "aryl" refers to an aromatic group, such as phenyl or napthyl, or a heteroatomic group containing one or more heteroatom, such as pyridyl, pyrrolyl, furanyl and thiophenyl. This term is not limited to a monovalent radical. The term 25 "aromatic" refers to any compound characterized by the presence of at least one benzene ring. Examples of aromatic groups include, but are not limited to, benzene and naphthalene.

The alkyl and aryl groups may be substituted or unsubstituted. The term "aliphatic" refers to any and all organic compounds of hydrogen and carbon 30 characterized by a straight chain of the carbon atoms. The subgroups of "aliphatic" compounds includes alkanes, alkenes, and alkynes. The aliphatic groups may be unsubstituted or substituted. See above for examples of substituents.

The term "alicyclic" refers to and covers any and all organic compounds of hydrogen and carbon atoms joined to form one or more rings. The alicyclic groups may be unsubstituted or substituted. See above for examples of substituents.

"Cycloalkyl" is intended to include saturated ring groups, such as cyclopropyl,
5 cyclobutyl, or cyclopentyl. This term is not limited to a monovalent radical. The cycloalkyl groups may be unsubstituted or substituted. See above for examples of substituents.

The term "alkenyl" refers to normal alkenyl, branch chain alkenyl and
10 cycloalkenyl groups having one or more sites of unsaturation. "Alkynyl" is intended to include hydrocarbon chains of either a straight or branched configuration and one or more triple carbon-carbon bonds which may occur in any stable point along the chain, such as ethynyl and propynyl. These terms are not limited to monovalent radicals. The alkenyl or alkynyl groups may be unsubstituted or substituted. See above for examples of substituents.

15 "Lower alkyl" means the above-defined broad definition of alkyl groups having 1 to 6 carbons in case of normal lower alkyl, and as applicable 3 to 6 carbons for lower branch chained (e.g., 2-methyl-propane) and cycloalkyl groups. "Lower alkenyl" is defined similarly having 2 to 6 carbons for normal lower alkenyl groups, and 3 to 6 carbons for branch chained and cyclo- lower alkenyl groups. "Lower alkynyl" is also 20 defined similarly, having 2 to 6 carbons for normal lower allynyl groups, and 4 to 6 carbons for branch chained lower alkynyl groups. The lower alkyl, alkenyl and alkynyl groups may be unsubstituted or substituted. See above for examples of substituents.

"Haloalkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, substituted 25 with 1 or more halogen (for example --C_vF_w where v=1 to 3 and w=1 to (2v+1)). The term haloalkyl is not limited to a monovalent radical. "Halogen" includes fluorine, chlorine, bromine, iodine and astatine. Examples of haloalkyl include, but are not limited to, trifluoromethyl, trichloromethyl, pentafluoroethyl, and pentachloroethyl.

30 The term "heterocyclic" refers to any compound in which the ring structure is a combination of more than one kind of atom. Examples of heterocyclic compounds include, but are not limited to, pyridine, furan and pyrrole. This term is not limited to a

monovalent radical. The heterocyclic groups may be unsubstituted or substituted. See above for definition of substituents.

As used herein the term "prodrug" means a precursor or derivative form of a pharmaceutically active agent or substance that is less cytotoxic to a target cell as compared to the drug metabolite and is capable of being enzymatically activated or converted into the more active form.

A "composition" is intended to mean a combination of active agent and another compound or composition, inert (for example, a surface, a paint, a detectable agent or label or a pharmaceutically acceptable carrier) or active, such as an adjuvant or disinfectant.

A "pharmaceutical composition" is intended to include the combination of an active agent with a carrier, inert or active, making the composition suitable for diagnostic or therapeutic use *in vitro*, *in vivo* or *ex vivo*.

The term "prophylactically effective amount" refers to an amount effective in preventing infection in a subject or plant infestation.

The term "pharmaceutically acceptable carrier" and "biologically acceptable carrier" refer to a carrier or adjuvant that is administered to a host or patient, together with a compound of this invention, and which does not destroy the pharmacological activity thereof and is non-toxic, when administered in doses sufficient to deliver an effective amount of the compound. Examples of suitable carriers include liquid phase carriers, such as sterile or aqueous solutions, as well as those described below.

Examples of pharmaceutically acceptable carrier include any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, and emulsions, such as an oil/water or water/oil emulsion, and various types of wetting agents. The compositions also can include stabilizers and preservatives. For examples of carriers, stabilizers and adjuvants, see Martin, REMINGTON'S PHARM. SCI., 15th Ed. (Mack Publ. Co., Easton (1975)).

The term "treating" refers to any of the following: the alleviation of symptoms of a particular disorder in a patient; the improvement of an ascertainable measurement associated with a particular disorder; or a reduction in microbial number. One of skill in the art can determine when a host has been "treated" by noting a reduction in microbial load or an alleviation in symptoms associated with infection.

The term "pharmaceutically acceptable salt, prodrug or derivative" relates to any pharmaceutically acceptable salt, ester, ether, salt of an ester, solvate, such as ethanolate, or other derivative of a compound of the present invention which, upon administration to a recipient, is capable of providing (directly or indirectly) a compound of this invention or an active metabolite or residue thereof. Particularly favored derivatives and prodrugs are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a mammal (e.g., by allowing an orally administered compound to be more readily absorbed into the blood) or which enhance delivery of the parent compound to a biological compartment (e.g., the brain or lymphatic system).

Salts of the compounds of the present invention may be derived from inorganic or organic acids and bases. Examples of acids include hydrochloric, hydrobromic, sulfuric, nitric, perchloric, fumaric, maleic, phosphoric, glycolic, lactic, salicylic, succinic, toluene-p-sulfonic, tartaric, acetic, citric, methanesulfonic, ethanesulfonic, formic, benzoic, malonic, naphthalene-2-sulfonic and benzenesulfonic acids. Other acids, such as oxalic, while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts. Examples of bases include alkali metal (e.g., sodium) hydroxides, alkaline earth metal (e.g., magnesium) hydroxides, ammonia, compounds of formula NW_4^+ , wherein W is C_{1-4} alkyl and THAM (2-amino-2-hydroxymethyl-1,3-propanediol).

Examples of salts include: acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, flucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, palmoate, pectinate, persulfate, phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate and undecanoate. Other examples of salts include anions of the compounds of the present invention compounded with a suitable cation such as Na^+ , Li^+ , NH_4^+ , and NW_4^+ (wherein W is a C_{1-4} alkyl group).

For therapeutic use, salts of the compounds of the present invention will be pharmaceutically acceptable. However, salts of acids and bases which are non-

pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound or for use to reduce microbial infestation in plants.

The term "traceless Linker" indicates a spacer or connector between two parts of 5 a single molecule such that when a particular bond is severed between the two parts of the molecule, the connector which is still attached to the second part of the molecule, eliminates leaving no trace of itself. *See*, for example, de Groot et al. (2000).

The term "effective amount" is to include therapeutically or prophylactically effective amounts. The term refers to an amount effective in treating or preventing an 10 infection in a patient or an infestation in a plant either as monotherapy or in combination with other agents.

"Inhibiting the growth" of a microorganism means reducing by contact with an agent, the rate of proliferation of such a microorganism, in comparison with a control microorganism of the same species not contacted with this agent.

A "subject" is any living being that is or can be a direct or indirect host to a PDF 15 expressing microorganism, including plants and animals such as a fish, an avian or a mammal, and preferably a human. Fish include, but are not limited to pets and aquaculture. Avians include, but are not limited to pets, sport animals and farm animals. Mammals include, but are not limited to, murines, simians, humans, farm animals, sport 20 animals, and pets.

Examples include, but are not limited to non-vertebrates, vertebrates, *e.g.*, avians or mammals, such as human patients. Mammals include, but are not limited to, murines, simians, humans, farm animals, sport animals, and pets.


25 PDF is a well-studied enzyme. The crystallographic structure of it is known. Chan et al. (1997). The enzyme has been expressed in *E. coli* BL21(DE3) cells Rajagopalan et al. (1997). The authors of the paper isolated the *E. coli def* gene by PCR using the primers designed based on the literature data on the sequence of the gene. The purified enzyme is unstable due to fast oxidation the catalytic site Fe²⁺ by the atmospheric oxygen. Rajagopalan et al. (1998). The conditions for proper handling the 30 enzyme to avoid inactivation have been reported. Rajagopalan et al. (1997). Importantly, Zn²⁺ and Ni²⁺ containing PDF's are stable allowing for the *in vitro*

evaluation of the enzyme catalytic properties. There exists a simple continuous colorimetric assay for PDF. Wei et al. (1997). It utilizes N-formylmethionylleucine p-nitroanilide as a substrate. A coupled aminopeptidase reaction that follows the PDF reaction releases p-nitroaniline that can be monitored spectrophotometrically at 405 nm.

5 PDF is a perfect ECTA target enzyme. It is active in bacteria and inactive in human hosts. It has broad substrate specificity. Deformylation liberates a free amino group of methionine (or another amino acid or an amino acid analog tolerated as an R₃ of the substrate, such as norleucine) which can perform a subsequent nucleophilic attack. With a rationally designed dipeptide or an equivalent peptidomimetic fragment 10 of the substrate the free amino group can attack an optimally positioned carbonyl group of the substrate thus forming a cyclic molecule (e.g. diketopiperazine, DKP) and releasing a toxin. The substrate can be optimized to enhance cyclization. The scheme of the proposed reaction exemplifying a dipeptide-based substrate is given in Figure 1. Here X can be, for example, sulfur (methionine) or -CH₂- (norleucine). R₁ and R₂ are 15 aliphatic radicals that can be selected based on the published SAR data for PDF. Hu et al. (1998).

Thus, in one aspect, the invention provides a prodrug compound having the structure:

20



wherein R₁, R₂, R₄, and R₅ are independently the same or different and are selected from the group consisting of hydrogen, a substituted or unsubstituted C₅-C₁₄ aryl group, a heteroaryl (for example, phenylmethylene, 4-hydroxypropyl, 3-aminopropyl, N-methyl-3-aminoethyl, 2-methoxymethyl, etc.), and a substituted or unsubstituted, saturated or unsaturated C₁-C₆ alkyl group (for example, methyl, ethyl, 3-hydroxypropyl, 3-aminopropyl, N-methyl-3-aminoethyl, 2-methoxymethyl, etc.);

wherein R₃ is selected from the group consisting of a substituted or unsubstituted aryl group (for example, phenylmethyl, triazolemethylene, thiophenemethylene, etc.),

and a substituted or unsubstituted, saturated or unsaturated C₁-C₆ alkyl group (for example ethyl, propyl, 2-hydroxyethyl, etc.) and -CH₂-CH₂-X-CH₃, wherein X is selected from the group consisting of -O-, -S-, -NH-, -NR₆-, and -CH₂-; where R₆ is a lower alkyl such as methyl or ethyl for example;

5 wherein A₁ and A₃ are independently the same or different and are selected from the group consisting of =O, =S, =NH, =N-OH, or =N-R₇, where R₇ is hydrogen or a C₁-C₆ alkyl, for example, methyl, ethyl or methoxymethyl;

10 wherein A₂, is absent or selected from the group consisting of =O, =S, =NH, =N-OH, =N-R₈, or -C(R₉)(R₁₀)-, wherein R₈, R₉, and R₁₀ are independently the same or different and are selected from the group consisting of hydrogen or a C₁-C₆ alkyl for example methyl, ethyl or methoxymethyl;

15 wherein B₁ is selected from the group consisting of -O-, -S-, -NH- or -N(R₁₁)-, wherein R₁₁ is selected from the group consisting of hydrogen and a C₁-C₆ alkyl for example methyl, ethyl or methoxymethyl;

20 wherein B₂ is absent or is selected from the group consisting of -O-, -S-, -N(R₁₂)-, or -C(R₁₃)(R₁₄)-, where R₁₂, R₁₃, and R₁₄ are independently the same or different and are selected from the group consisting of hydrogen or a substituted or unsubstituted, saturated or unsaturated alkyl for example methyl, ethyl or methoxymethyl;

25 wherein the fragment -B₂-C(R₄)(R₅)-C(=A₃) - in its entirety is one of the twenty naturally occurring amino acids, e.g., proline, an analog, derivative or peptidomimetic thereof;


 wherein the fragment -B₂-C(R₄)(R₅)-C(=A₃) - in its entirety is proline, an analog, derivative or peptidomimetic thereof;

30 wherein B₃ is absent or is selected from the group consisting of -O-, -S-, or -NH-, or -N(R₁₅)-, wherein R₁₅ is selected from the group consisting of hydrogen and a C₁-C₆ alkyl for example methyl, ethyl or methoxymethyl;

 wherein B₄ is absent or is selected from the group consisting of -O-, -S-, -N(R₆)-, and -C(R₁₆)(R₁₇)- and wherein R₁₆ and R₁₇ are independently the same or different and are selected from the group consisting of hydrogen or a substituted or

unsubstituted, saturated or unsaturated alkyl, for example methyl, ethyl or methoxymethyl;

wherein a linker is absent or is a traceless linker is selected from the group consisting of, but not limited to, -C₆H₄-CH₂- and -C₆H₄-CH₂-X₁-C(=X₂)- wherein X₁ and X₂ are independently the same or different are selected from the group consisting of -O-, -S- and -N(R_a) where R_a is -hydrogen or a lower alkyl; and -(CH₂)_n-NR_b-(C=O)- which has the structure:



10

wherein n = 2 or 3 and R_b is hydrogen or a lower alkyl;

and wherein a toxin is a cytotoxic or antibiotic molecule that is released upon activation by an enzyme, with the proviso that the toxin is not 5-F-dUrd.

Examples of toxins include, but are not limited to a group consisting of
 15 fluorquinolones, aminoglycosides, mitomycin, CC-1065, ducarmycin, CBI analogs, anthracyclines, vinca alkaloids, mitomycins, bleomycins, penicillins, cephalosporins, oxacillins, carbopenems, tetracyclines, chloramphenicols, macrolides, cycloserines, fluoroquinolones (including, but not limited to, ciprofloxacin and norfloxacin), glycopeptides, aminoglycosides, peptide antibiotics, oxazolidinones, quinolones,
 20 sulfonamides, cytotoxic nucleosides, pteridine family, nitrogen mustards, polyhalogenated biaryl ethers, diynenes, podophyllotoxins, taxoids, doxorubicin, carminomycin, daunorubicin, aminopterin, methotrexate, methopterin, dichloromethotrexate, mitomycin C, porfiromycin, 6-mercaptopurine, cytosine arabinoside, podophyllotoxin, etoposide, etoposide phosphate, melphalan, vindesine,
 25 vinblastine, vincristine, leurosidine, leurosine, bis-(2-chloroethyl)amine, trichlorcarban, trichlorocarbanilide, tribromosalicylanilide, sulphamethoxazole, chloramphenicol, cycloserine, trimethoprim, chlorhexidine, hexachlorophene, fentichlor, 5-chloro-2-(2,4-dichlorophenoxy)phenol, 4-chloro-2-(2,4-dichlorophenoxy)phenol, 3-chloro-2-(2,4-dichlorophenoxy)phenol, 6-chloro-2-(2,4-dichlorophenoxy)phenol, 5-chloro-2-(3,4-dichlorophenoxy)phenol, 5-chloro-2-(2,5-dichlorophenoxy)phenol, 5-chloro-2-(3,5-

dichlorophenoxy)phenol, 2,2'-dihydroxy biphenyl ether, halogenated 2-hydroxybenzophenones, 2-mercaptopyridine-N-oxide, combretastatin, camptothesin, apoptolidene, cisplatin, epothilone, halichondrin, hemiasterlin, methioprim, thapsigargin, chloroquine, 4-hydroxycyclophosphamide, etoposide, colchicine, 5 melphalan, quercetin, genistein, erbstatin, N-(4-aminobutyl)-5-chloro-2-naphthalen-sulfonamide, pyridinyloxazol-2-one, isoquinolyloxazolone-2-one, verapamil, quinine, quinidine, and chloroquine.

In a further aspect, the compound is as noted above but the toxin is selected from the group consisting of 2-mercaptopyridine-N-oxide, ciprofloxacin, norfloxacin, and 10 nitrogen mustard, and the derivatives and analogs thereof.


In one aspect, the compound is as noted above but B_2 is $-NH$, B_3 is $-O-$, R_4 is 2-methyl-propyl and R_5 is hydrogen.



In one aspect, the fragment $-B_2-C(R_4)(R_5)-C(=A_3)$ – in its entirety is a naturally occurring amino acid such as proline, a derivative or analog thereof, or a 15 peptidomimetic thereof

In one aspect, wherein the fragment $-B_2-C(R_4)(R_5)-C(=A_3)$ – in its entirety is proline, a derivative or analog thereof, or a peptidomimetic thereof;

In one aspect, the compound has the structure as set forth above, with the proviso that the toxin is selected from the group of structures consisting of:

20





5

and derivatives, analogs and salts thereof. It will be appreciated that various modifications to the above toxins can be made without an appreciable loss of activity.


In one aspect, the compound is as noted above but R₁ and R₂ are both hydrogen.

10 In a further aspect, the compound is as noted above but R₃ is -CH₂-CH₂-X-CH₃, wherein X is selected from the group consisting of oxygen, sulfur or methyl. In a further aspect, X is sulfur.

In a further aspect, the compound is as noted above but A₁ and A₂ are both oxygen.

In a further aspect, the compound is as noted above but B₁ is -NH-.

15 In a further aspect, the compound is as noted above but the linker has the following structure:




20 In a further aspect, the compound is as noted above but B₄ is absent.

In one aspect, the compound is 2-(2-formylamino-4-methylsulfanylbutyrylamino)-4-methyl-pentanoic acid 4-(N-oxide-pyridin-2-ylsulfanylmethyl)-phenyl ester compound and has the structure:

NB3024

5




In another aspect, the compound is 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4,4a,8a-tetrahydro-quinoline-3-carboxylic acid 4-[2-(2-formylamino-4-

10 methylsulfanylbutyrylamino)-4-methyl-pentanoyloxy]-benzyl ester that has the structure:

NB3057


15



In one aspect, the compound is 1-ethyl-6-fluoro-7-(4-{4-[2-(2-formylamino-4-methylsulfanyl-butylamino)-4-methyl-pentanoyloxy]-benzyloxycarbonyl}-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid that has the structure:


NB3068

5




In a further aspect, the compound is *tert*-butoxycarbonylamino-4-methyl-pentanoic acid-5-chloro-2-(2,4-dichloro-phenoxy)-phenyl ester and has the structure:

10



In another aspect, the compound is 2-(2-formylamino-4-methylsulfanylbutyrylamino)-4-methyl-pentanoic acid 5-chloro-2-(2,4-dichloro-phenoxy)-phenyl ester and has the structure:

NB2046




5


In one aspect, the compound is 2-(2-formylamino-4-methylsulfanylbutyrylamino)-4-methyl-pentanoic acid 4-{{[bis-(2-chloro-ethyl)-carbamoyloxy]-methyl}-phenyl ester and has the structure:

10


NB3103




In a further aspect, the compound is -tert-Butoxycarbonylamino-4-methyl-pentanoic acid 4-formyl-phenyl ester and has the structure:



5 In a further aspect, the compound is 2-(2-formylamino-4-methylsulfanylbutyrylamino)-4-methyl-pentanoic acid 4-hydroxymethyl-phenyl ester which has the structure:



10 In a further aspect, the compound is 2-(2-Formylamino-4-methylsulfanylbutyrylamino)-4-methyl-pentanoic acid 4-chloromethyl-phenyl ester and has the structure:



15 Any of the above noted compounds can be combined with a carrier, such as a pharmaceutically acceptable carrier or an additional effective agent such as an antibiotic. These compounds and compositions are also useful to be used in combination with known or yet to be discovered therapeutics and therapeutic methods to enhance the therapy or efficacy of the drug.

Also provided by this invention is a method for inhibiting the growth of a PDF expressing microorganism by contacting the microorganism with an effective amount of the compound as described above. Methods to detect PDF expression are known in the art. See, for example, Wei, et al. (1997). This method is particularly useful in inhibiting the growth of gram-positive and gram-negative microorganisms, e.g., of *S. aureus*, *S. epidermidis*, *K. pneumoniae*, *E. aerogenes*, *E. cloacae*, *M. catarrhalis*, *E. coli*, *E. faecalis*, *H. influenzae* and *P. aeruginosa*, and those identified in Table 2, below.

Further provided is a method for alleviating the symptoms of an infection in a subject, wherein the infection is caused by a PDF expressing microorganism, by administering or delivering to the subject an effective amount of the compound described above. Also provided by this invention is a method for treating an infection caused by a PDF expressing microorganism by administering or delivering to the subject an effective amount of the compound described above. A "subject" is defined above and includes mammals such as human patients. Examples of PDF expressing microorganisms and the corresponding diseases and symptoms caused by infection by these microorganisms, are provided in Table 2, below.

Table 2

<i>PDF Expressing Microorganism</i>	<i>Disease or Symptom Caused by Infection</i>
Gram-Positive	
<i>Staphylococcus aureus</i>	major human pathogen, bacteremia, pneumonia
<i>Staphylococcus epidermidis and other coagulase-negative staphylococci</i>	urinary tract infections, osteomyelitis, bacteremia
<i>Streptococcus pyogenes</i>	bacteremia, lymphangitis, pneumonia
<i>Streptococcus pneumoniae</i>	pneumonia, otitis media, sinusitis
<i>Streptococcus agalactiae</i>	primary bacteremia, pneumonia, endocarditis, osteomyelitis
<i>Enterococcus species</i>	urinary tract infections, bacteremia, endocarditis, intra-abdominal and pelvic infections, neonatal sepsis
<i>Neisseria gonorrhoeae</i>	genital infection, perihepatitis
<i>Moraxella catarrhalis</i>	otitis media, lower respiratory tract infections, pneumonia, bacteremia
<i>Campylobacter jejuni</i>	acute enteritis, acute colitis, bacteremia
<i>Enterobacteriaceae (including Escherichia, Salmonella, Klebsiella, Enterobacter)</i>	enteric infections, urinary tract infections, respiratory infections, bacteremia

<i>PDF Expressing Microorganism</i>	<i>Disease or Symptom Caused by Infection</i>
Gram-Positive	
<i>Pseudomonas aeruginosa</i>	endocarditis, respiratory infections, bacteremia, central nervous system infections
<i>Acinetobacter species</i>	respiratory tract infections, bacteremia, genitourinary
<i>Haemophilus influenzae</i>	meningitis, epiglottitis, pneumonia, bacteremia

This invention also provides a composition comprising the prodrug compounds as described above, alone or in combination with other compounds or other agents, known or yet to be discovered, and a carrier. In one embodiment, the carrier is a 5 pharmaceutically acceptable carrier.

In the clinical use of the prodrug, antibiotics will likely follow well established guidelines. Dosage will likely be similar to those already employed for most other antibiotics. It is estimated that a dose of prodrug will be in the range of 100 µg to 100 mg to 1 gm, or given once every eight hours, or once a day, for one or two weeks, or 10 until the patient tests negative for infectious organisms.

In one aspect, the invention encompasses a method of treating or protecting plants from infections caused by PDF expressing microorganisms by applying an effective amount of the substrate prodrug.

In order to achieve good dispersion and adhesion of the compounds as used to 15 treat plants, it may be advantageous to formulate the compounds with components that aid dispersion and adhesion. Suitable formulations will be known to those skilled in the art.


This invention also provides a method for treating or protecting plants from 20 infection by microorganisms expressing PDF by applying an effective amount of the prodrug compound to the foliage, roots or the soil surrounding the plants or roots. These isolated compounds can be combined with known pesticides or insecticides.

Compounds within the present invention when used to treat or protect plants from infections caused by PDF expressing microorganisms can be formulated as 25 wettable powders, granules and the like, or can be microencapsulated in a suitable medium and the like. Examples of other formulations include, but are not limited to

soluble powders, wettable granules, dry flowables, aqueous flowables, wettable dispersible granules, emulsifiable concentrates and aqueous suspensions. Other suitable formulations will be known to those skilled in the art.

This invention further provides a method for administering the prodrug
5 compound to fish in an amount effective to either prevent or treat an infection caused by PDF expressing microorganisms. The compound may be administered by incorporating the compound into the food supply for the fish. Alternatively, the compound may be added to the water in which fish live, or are contained within. Finally, the compound may be administered to the fish as a suitable pharmaceutical preparation. Other suitable
10 formulations will be known to those skilled in the art.

Further provided is a process for producing the prodrugs of this invention. In general the process requires the following steps:



With respect to the above diagram, X can be sulfur (methionine) or $-\text{CH}_2-$ 5 (norleucine). R_1 through R_5 and B_1 through B_3 are as defined above. Reaction conditions and full names for the abbreviations can be found in the experimental examples *infra*.

This invention provides a method for identifying potential therapeutic agents that inhibit the growth of an organism expressing PDF by contacting a sample containing the 10 PDF expressing microorganism with an effective amount of a candidate prodrug compound. In a separate sample, the same microorganism is contacted with an effective amount of a prodrug of this invention. If the agent has comparable anti-proliferative ability

as compared to a prodrug as described herein, the candidate is useful to inhibit the growth or kill a PDF-expressing microorganism.

The prodrug is contacted with the sample under conditions that favor the activation of the prodrug by PDF and then assaying the sample growth inhibition or microbial death.

5 Alternatively, the sample can be tested for the presence of the byproducts of the reaction of PDF on the substrate. Varying amounts of the substrate is contacted with a microorganism that expresses PDF for an amount of time effective for PDF to release the toxin from the cell, the bacteria is lysed and the analytes are analyzed using methods well known in the art (e.g., High Performance Liquid Chromatography ("HPLC")) to identify the reaction products.

10 Varying concentrations of the potential agent are contacted with the sample to determine the optimal effective concentration of the agent. Thus, in one aspect, this invention relates to the discovery, and use thereof, of agents that are selective substrates for PDF.

15 Also provided by this invention are kits containing the prodrugs as described herein and instructions necessary to perform the screen.

20 The methods of the invention can be practiced *in vitro*, *ex vivo* or *in vivo*. *In vivo* practice of the invention in an animal such as a rat or mouse provides a convenient animal model system that can be used prior to clinical testing of the therapeutic agent or prodrug. In this system, a potential prodrug will be successful if microbial load is reduced or the symptoms of the infection are ameliorated, each as compared to an untreated, infected animal. It also can be useful to have a separate negative control group of cells or animals which has not been infected, which provides a basis for comparison.

25 When practiced *in vivo*, the candidate prodrug is administered or delivered to the animal in effective amounts. As used herein, the term "administering" for *in vivo* and *ex vivo* purposes means providing the subject with an effective amount of the candidate prodrug effective to reduce microbial load. In these instances, the agent or prodrug may be administered with a pharmaceutically acceptable carrier. The agents, prodrugs and 30 compositions of the present invention can be used in the manufacture of medicaments and for the treatment of humans and other animals by administration in accordance with conventional procedures, such as an active ingredient in pharmaceutical compositions.

Methods of administering pharmaceutical compositions are well known to those of ordinary skill in the art and include, but are not limited to, microinjection, intravenous or parenteral administration. The compositions are intended for topical, oral, or local administration as well as intravenously, subcutaneously, or intramuscularly.

5 Administration can be effected continuously or intermittently throughout the course of the treatment. Methods of determining the most effective means and dosage of administration are well known to those of skill in the art and will vary with the prodrug used for therapy, the purpose of the therapy, the microorganism being treated, the severity of the infection, and the subject being treated. Single or multiple

10 administrations can be carried out with the dose level and pattern being selected by the treating physician. For example, the compositions can be administered to a subject already suffering from an antibiotic resistant bacterial infection. In this situation, an effective "therapeutic amount" of the composition is administered to prevent continued and to at least partially arrest microbial growth and proliferation and ameliorate the

15 symptoms associated with an infection.

However, the prodrugs can be administered to subjects or individuals susceptible to or at risk of developing an infection. In these embodiments, a "prophylactically effective amount" of the composition is administered to maintain cell viability and function at a level near to the pre-infection level.

20 Administration *in vivo* can be effected in one dose, continuously or intermittently throughout the course of treatment. Methods of determining the most effective means and dosage of administration are well known to those of skill in the art and will vary with the composition used for therapy, the purpose of the therapy, the target cell being treated, and the subject being treated. Single or multiple

25 administrations can be carried out with the dose level and pattern being selected by the treating physician. Suitable dosage formulations and methods of administering the agents can be found below.

The pharmaceutical compositions can be administered orally, intranasally, parenterally or by inhalation therapy, and may take the form of tablets, lozenges, granules, capsules, pills, ampoules, suppositories or aerosol form. They may also take the form of suspensions, solutions and emulsions of the active ingredient in aqueous or nonaqueous diluents, syrups, granulates or powders. In addition to an agent of the

present invention, the pharmaceutical compositions can also contain other pharmaceutically active compounds or a plurality of compounds of the invention.

More particularly, an agent of the present invention also referred to herein as the active ingredient, may be administered for therapy by any suitable route including oral, 5 rectal, nasal, topical (including transdermal, aerosol, buccal and sublingual), vaginal, parenteral (including subcutaneous, intramuscular, intravenous and intradermal) and pulmonary. It will also be appreciated that the preferred route will vary with the condition and age of the recipient, and the disease being treated.

Ideally, the agent should be administered to achieve peak concentrations of the 10 active compound at sites of disease. This may be achieved, for example, by the intravenous injection of the agent, optionally in saline, or orally administered, for example, as a tablet, capsule or syrup containing the active ingredient. Desirable blood levels of the agent may be maintained by a continuous infusion to provide a therapeutic amount of the active ingredient within disease tissue. The use of operative 15 combinations is contemplated to provide therapeutic combinations requiring a lower total dosage of each component agent than may be required when each individual therapeutic compound or drug is used alone, thereby reducing adverse effects.

While it is possible for the agent to be administered alone, it is preferable to 20 present it as a pharmaceutical formulation comprising at least one active ingredient, as defined above, together with one or more pharmaceutically acceptable carriers therefor and optionally other therapeutic agents. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient.

Formulations include those suitable for oral, rectal, nasal, topical (including 25 transdermal, buccal and sublingual), vaginal, parenteral (including subcutaneous, intramuscular, intravenous and intradermal) and pulmonary administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. Such methods include the step of bringing into association the active ingredient with the carrier that constitutes one or 30 more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then if necessary shaping the product.

Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets, each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or 5 a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste.

A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or 10 granules, optionally mixed with a binder (e.g., povidone, gelatin, hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (e.g., sodium starch glycolate, cross-linked povidone, cross-linked sodium carboxymethyl cellulose) surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.

15 The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile. Tablets may optionally be provided with an enteric coating, to provide release in parts of the gut other than the stomach.

20 Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.

25 Pharmaceutical compositions for topical administration according to the present invention may be formulated as an ointment, cream, suspension, lotion, powder, solution, past, gel, spray, aerosol or oil. Alternatively, a formulation may comprise a patch or a dressing such as a bandage or adhesive plaster impregnated with active ingredients and optionally one or more excipients or diluents.

30 If desired, the aqueous phase of the cream base may include, for example, at least about 30% w/w of a polyhydric alcohol, i.e., an alcohol having two or more hydroxyl groups such as propylene glycol, butane-1,3-diol, mannitol, sorbitol, glycerol

and polyethylene glycol and mixtures thereof. The topical formulations may desirably include a compound that enhances absorption or penetration of the agent through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethylsulfoxide and related analogues.

5 The oily phase of the emulsions of this invention may be constituted from known ingredients in an known manner. While this phase may comprise merely an emulsifier (otherwise known as an emulgent), it desirably comprises a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier that acts as a 10 stabilizer. It is also preferred to include both an oil and a fat. Together, the emulsifier(s) with or without stabilizer(s) make up the so-called emulsifying wax, and the wax together with the oil and/or fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations.

15 Emulgents and emulsion stabilizers suitable for use in the formulation of the present invention include Tween 60, Span 80, cetostearyl alcohol, myristyl alcohol, glycceryl monostearate and sodium lauryl sulfate.

20 The choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties, since the solubility of the active compound in most oils likely to be used in pharmaceutical emulsion formulations is very low. Thus, the cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers. Straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters known as 25 Crodamol CAP may be used; the last three being preferred esters. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be used.

30 Formulations suitable for topical administration to the eye also include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the agent.

Formulations for rectal administration may be presented as a suppository with a suitable base comprising, for example, cocoa butter or a salicylate.

Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the agent, such carriers as are known in the art to be appropriate.

Formulations suitable for nasal administration, wherein the carrier is a solid, include a coarse powder having a particle size, for example, in the range of about 20 to about 500 microns which is administered as a dry powder or in an inhaler device by rapid inhalation through the nasal passage from a container of the powder held close up to the nose. Suitable formulations wherein the carrier is a liquid for administration as, for example, nasal spray, nasal drops, or by aerosol administration by nebulizer, include aqueous or oily solutions of the agent.

Formulations suitable for parenteral administration include aqueous and non-aqueous isotonic sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents, and liposomes or other microparticulate systems which are designed to target the compound to blood components or one or more organs. The formulations may be presented in unit-dose or multi-dose sealed containers, for example, ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.

Preferred unit dosage formulations are those containing a daily dose or unit, daily subdose, as herein above-recited, or an appropriate fraction thereof, of a agent.

It should be understood that in addition to the ingredients particularly mentioned above, the formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example, those suitable for oral administration may include such further agents as sweeteners, thickeners and flavoring agents. It also is intended that the agents, compositions and methods of this invention be combined with other suitable compositions and therapies.

These agents of this invention and the above noted compounds and their derivatives may be used for the preparation of medicaments for use in the methods described herein.

In the clinical use of the prodrug antibiotics will likely follow well established
5 guidelines. Dosage will likely be similar to those already employed for most other antibiotics. It is estimated that a dose of prodrug will be in the range of 100 mg to 1 gm, given once every eight hours, or once a day, for one or two weeks, or until the patient tests negative for infectious organisms.


The following examples are intended to illustrate, but not limit the invention.

10

Example 1 – Synthetic Scheme

The following examples of the synthesis of the claimed compounds are meant to be illustrative of the synthesis of the invention and not limit the synthesis of the
15 invention. The synthetic methods, as for example seen below, used to synthesize the compounds are well known to those skilled in the art of organic and medicinal chemistry. Substitutions, modifications or additional steps used in the synthesis of the compounds of the present invention well known to those skilled in the art of organic and medicinal chemistry are anticipated. See, e.g., J. March, ADVANCED ORGANIC
20 CHEMISTRY: REACTIONS, MECHANISMS AND STRUCTURE, 4th edition (John Wiley & Sons, NY (1992)).

Synthesis of Compound #1 and NB2046



In the above synthetic scheme and the following examples, the following acronyms and definitions apply: N-*tert*-butoxycarbonyl (BOC); 5 benzotriazol-1-yloxytris(dimethylamino) phosphonium hexafluorophosphate (BOP); – triethylamine (TEA); tetrahydrofuran (THF); room temperature (RT); trifluoroacetic acid (TFA); sodium borohydride (NaBH_4); phosphorous pentachloride (PCl_5); dimethylformamide (DMF); N-methyl-N-trimethylsilyltrifluoroacetamide (MSTFA); diisopropylethylamine (DIEA); and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU).

10

Synthesis of Compound 1 – Intermediate to Compound NB2046.

A solution of BOC leucine (1.0 g, 4.32 mmol), tricosan (1.25 g, 4.32 mmol), benzotriazol-1-yloxytris(dimethylamino) phosphonium hexafluorophosphate (1.91 g, 4.32 mmol), and triethylamine (1.33 g, 12.9 mmol) in anhydrous THF (25 ml) was 15 stirred at 0 °C under argon atmosphere for 4 hours. Water (20 ml) was added and the reaction mixture was extracted with ethylacetate (2 X 30 ml). Combined organic layers were washed with water, brine, and dried over Na_2SO_4 . Evaporation of the solvent and purification using silica gel column chromatography with 2% ethylacetate in hexane as eluant provided compound 1 as a colorless gum (1.66 g, 75%).

¹H NMR (CDCl₃, 500 MHz): 0.91 (d, 2H, J = Hz), 1.43 (s, 9H), 1.51-1.60 (m, 2H), 1.69-1.73 (m, 1H), 4.43-4.48 (m, 1H), 4.83 (d, 1H, J= Hz), 6.80 (d, 1H, J= Hz), 6.86 (d, 1H, J= Hz), 7.14-7.26 (m, 2H), 7.26 (s, 1H), 7.43 (d, 1H, J = Hz).

5 *Synthesis of Compound NB2046.*


A solution of compound-1 (0.25 g, 0.5 mmol), in anhydrous anisole (0.055 g, 0.5 mmol), was cooled to 0 °C and TFA (0.56 g, 5.0 mmol) was added slowly over 15 minutes. The ice bath was removed and stirring continued for another 3 hours. All the volatiles were then removed under reduced pressure to get a gum. Anhydrous THF was 10 added and cooled to 0 °C under argon atmosphere. Benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (0.25 g, 0.57 mmol), N-formyl methionine (0.1 g, 0.57 mmol), and triethylamine (0.21 g, 2.1 mmol) were added. Thin layer chromatography showed the completion of reaction after 0.5 hour at 0 °C. The reaction was washed with water, brine, and dried Na₂SO₄. Purification on 15 silica gel column chromatography provided NB2046 as colorless thick gum.

¹H NMR (CDCl₃, 500 MHz): 0.88 (d, 3H, J = Hz), 0.91 (d, J = Hz), 1.50 – 1.56 (m, 1H), 1.60 – 1.71 (m, 2H), 1.95-2.02 (m, 1H), 2.09 (s, 3H), 2.50 (m, 1H), 2.58 (m, 1H), 4.65-4.70(m, 1H), 4.74 (q, 1H, J = Hz), 6.48 (d, 1H), 6.78-6.85 (m, 2H), 7.15-7.25 (m, 3H), 7.44 (s, 1H), 8.17 (s, 1H).

20


General Synthetic Scheme of Intermediates (Compounds 3 and 4) to Compounds NB3024, NB3057, NB3068 and NB3103:

The following examples of the synthesis of the claimed compounds are meant to be illustrative of the synthesis of the invention and not limit the synthesis of the 25 invention. The synthetic methods, as for example seen below, used to synthesize the compounds are well known to those skilled in the art of organic and medicinal chemistry. Substitutions, modifications or additional steps used in the synthesis of the compounds of the present invention well known to those skilled in the art of organic and medicinal chemistry are anticipated. See, e.g., J. March, ADVANCED ORGANIC 30 CHEMISTRY: REACTIONS, MECHANISMS AND STRUCTURE, 4th edition (John Wiley & Sons, NY (1992)).



Detailed Description of Synthetic Scheme of Intermediates

Synthesis of 2-tert-Butoxycarbonylamino-4-methyl-pentanoic acid 4-formyl-phenyl ester (Compound 1)




BOP (13.0 mmol) was added to a solution of N-tert-butoxycarbonyl-L-leucine (10.9 mmol) and 4-hydroxybenzaldehyde (13.0 mmol) in dry DMF (12 mL), and stirred 10 to dissolve. N,N-Diisopropylethylamine (43.0 mmol) and 4-dimethylaminopyridine (1 mmol) were added with stirring. The resulting solution was stirred for 2.5 hours. The reaction mixture was covered with dichloromethane (100 mL) and washed with water, saturated aqueous sodium bicarbonate, and saturated brine. The dichloromethane was

dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The resulting red oil was purified by column chromatography on silica gel with dichloromethane as an eluant.

¹H NMR (CDCl₃, 500 MHz): 1.01-1.02 (m, 6H), 1.46 (s, 9H), 1.64 – 1.68 (m, 1H), 1.76-1.83 (m, 2H), 4.52-4.54 (m, 1H), 4.92-4.94 (d, 2H, J = 7.6 Hz), 7.28-7.29 (d, 2H, J = 8.48 Hz), 7.91-7.93 (d, 2H, J = 8.48 Hz), 9.99 (s, 1H).


Synthesis of 2-(2-Formylamino-4-methylsulfonyl-butyrylamino)-4-methyl-pentanoic acid 4-formyl-phenyl ester (Compound 2)

10



A solution of compound 1 (10 mmol) in TFA (100 mmol) was stirred at RT for 1 hour under inert atmosphere. All the volatiles were then removed under reduced pressure and the residue was dissolved in THF (10 mL). N-formyl-L-methionine (10 mmol), BOP (13.0 mmol), followed by N,N-Diisopropylethylamine (30.0 mmol) and 4-dimethylaminopyridine (1mmol) were added with stirring. After the completion of reaction, THF was removed under reduced pressure and dichloromethane (25 ml) was added. The reaction mixture was washed with water, saturated aqueous sodium bicarbonate, and saturated brine. The dichloromethane was dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The resulting think gum was purified by column chromatography on silica gel with 0 to 5% methanol in dichloromethane as an eluant.

Synthesis of 2-(2-formylamino-4-methylsulfanylbutyrylamino)-4-methylpentanoic acid 4-hydroxymethyl-phenyl ester (Compound 3)




5 To synthesize the above compound, a solution of compound 2 (1.0 mmol) in methanol (10 mL) was cooled to 0 °C and a solution of NaBH₄ (0.25 mmol) in methanol was slowly added. After 5 min 0.1 N HCl was added and the volatiles were removed at reduced pressure. The resultant mixture was partitioned between water and ethyl acetate (10 mL). Separated ethyl acetate layer was washed with brine and dried over Na₂SO₄.

10 Removal of volatiles provided compound 3 in quantitative yield as light yellow gum.

¹H NMR (CDCl₃, 500 MHz) 0.99-1.03 (m, 6H), 1.71 – 1.87 (m, 3H), 2.02-2.15 (m, 2H), 2.11 (s, 3H), 2.53-2.66 (m, 2H), 4.68 (s, 2H), 4.76-4.79 (m, 2H), 6.46-6.47 (m, 1H), 6.70-6.74 (m, 1H), 7.06-7.08 (m, 2H), 7.36-7.39 (m, 2H), 8.19 (s, 1H).

15

Synthesis of 2-(2-Formylamino-4-methylsulfanylbutyrylamino)-4-methylpentanoic acid 4-chloromethyl-phenyl ester (Compound 4)




20

A solution of compound 3 (0.2 grams, 0.55 mmol) in anhydrous dichloromethane was cooled in an ice bath and PCl₅ (0.11 grams, 0.55 mmol) was added under argon atmosphere. After the completion of the reaction aqueous NaHCO₃ was

added and stirred for 10 min. Organic layer was separated, washed with water, brine and dried (Na_2SO_4). Evaporation of volatiles provided the title compound, which was used for the next reaction without further purification.


¹H NMR (CDCl_3 , 500 MHz): 1.00-1.03 (m, 6H), 1.72 – 1.86 (m, 3H), 2.02-2.15 (m, 2H), 2.1 (s, 3H), 2.53-2.66 (m, 2H), 4.57 (s, 2H), 4.75-4.81 (m, 2H), 6.46-6.47 (m, 1H), 6.73-6.77 (m, 1H), 7.07-7.10 (m, 2H), 7.38-7.41 (m, 2H), 8.20 (s, 1H).

Synthetic Scheme of Synthesis of Compound NB3024



¹⁰ *Detailed Description of Synthesis of Compound NB3024*

2-(2-Formylamino-4-methylsulfanylbutyrylamino)-4-methyl-pentanoic acid
4-(1-hydroxy-1,2-dihydro-pyridin-2-ylsulfanyl)methyl-phenyl ester
(NB3024)




¹⁵

To a solution of compound 4 (1.0 mmol) in anhydrous DMF (2 mL) sodium bicarbonate (2.5 mmol) and pyritthione (1.0 mmol) was added and stirred under inert atmosphere for 1 hr. Reaction mixture was then filtered and DMF was removed under reduced pressure. Passing it through a short silica gel column purified the crude product.

²⁰

¹H NMR (CDCl_3 , 500 MHz): 0.98-1.02 (m, 6H), 1.71 – 1.84 (m, 3H), 2.02-2.21 (m, 2H), 2.14 (s, 3H), 2.60-2.66 (m, 2H), 4.15 (s, 2H), 4.75-4.78 (m, 2H), 6.48-6.50 (m, 1H), 6.70-6.74 (m, 1H), 7.06-7.08 (m, 3H), 7.12 (d, 1H, $J = 7.7$ Hz), 7.21-7.24 (m, 1H) 7.36-7.39 (m, 2H), 8.19 (s, 1H), 8.26 (d, 1H, $J = 6.36$ Hz).


Synthetic Scheme of Synthesis of Compound NB3057

5

Detailed Description of Synthesis of Compound NB3057

1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylic acid 4-[2-(2-formylamino-4-methylsulfanylbutyrylamino)-4-methyl-pentanoyloxy]-benzylester

10




To a solution of compound 3 (1.0 mmol) and BOC-ciprofloxacin (1.0 mmol) in anhydrous dichloromethane (10 mL), EDCI (2.0 mmol) was added. After 48 hrs at RT
15 the crude reaction mixture was loaded on a silica gel column and the product was eluted with 5% methanol in dichloromethane.

¹H NMR (DMSO-d6), 500 MHz): 0.89-0.91 (m, 3H), 0.94-0.96 (m, 3H), 1.10-1.12 (m, 2H), 1.25 – 1.26 (m, 2H), 1.70-1.75 (m, 4H), 2.02-2.15 (m, 2H), 2.11 (s, 3H),

3.44 (brs, 4H), 3.78 (brs, 4H), 3.42-3.44 (m, 1H), 4.50-4.55 (m, 2H), 5.27 (s, 2H), 7.08-7.10 (m, 2H), 7.47-7.49 (m, 1H), 7.53-7.55 (m, 1H), 7.85 (d, 1H, J= 12 HZ), 8.02 (s, 1H), 8.35(t, 1H, J = 12.64 Hz), 8.50 (s, 1H), 8.62- 8.68 (m, 1H), 8.79 (s, 2H).

Synthetic Scheme of Synthesis of Compound NB3068




5

NB3068

Detailed Description of Synthesis of NB3068

1-Ethyl-6-fluoro-7-(4-{4-[2-(2-formylamino-4-methylsulfonyl)butyrylamino)-4-methyl-pentanoyloxy]-benzyloxycarbonyl}-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid (NB3068)

10




To a mixture of norfloxacin (84 mg, 0.26 mmol) in anhydrous dichloromethane (2 mL) MSTFA (100 mg, 0.5 mmol) was added and stirred for 30 min at RT. In the mean time a solution of compound 3 (140 mg, 0.35 mmol) and DIEA (70 mg, 0.4 mmol) was taken in another flask and phosgene (40 mg, 0.4 mmol) was added at 0 °C. This solution was then added to the solution of norfloxacin and stirred at room

temperature for 1 hour. The reaction mixture was washed with 0.1 N HCl and dried over Na₂SO₄. Volatiles were removed and ether (5 mL) was added. The precipitated product was then filtered.

5 ¹H NMR (CDCl₃, 500 MHz): 0.99-1.03 (m, 6H), 1.55 (m, 3H), 1.71 – 1.87 (m, 3H), 2.02-2.15 (m, 2H), 2.11 (s, 3H), 2.53-2.66 (m, 2H), 3.27 (brs, 4H), 3.78 (brs, 4H), 4.30 (q, 2H, J = 7.19, 14.44 Hz), 4.76-4.80 (m, 2H), 5.15 (s, 2H), 6.46-6.47 (m, 1H), 6.71-6.72 (m, 1H), 6.83 (d, 1H, J = 6.87 Hz), 7.08-7.10 (m, 2H), 7.38-7.41 (m, 2H), 8.10 (d, 1H, J = 12.64 Hz), 8.21 (s, 1H), 8.68 (s, 1H).

10


Synthetic Scheme of Synthesis of Compound NB3103



Detailed Description for Synthesis of NB3103

15

2-(2-Formylamino-4-methylsulfanyl-butylamino)-4-methyl-pentanoic acid
4-{[bis-(2-chloro-ethyl)-carbamoyloxy]-methyl}-phenyl ester (NB3103)



To a solution of compound 3 in anhydrous dichloromethane bis-dichloroethane carbamoyl chloride and DBU were added at room temperature. After 15 minutes the reaction mixture was washed with water (10 mL) and purified on silica gel column.

¹H NMR (CDCl₃, 500 MHz): 0.99-1.03 (m, 6H), 1.71 – 1.84 (m, 3H), 2.02-2.21 (m, 2H), 2.11 (s, 3H), 2.64-2.67 (m, 2H), 3.57-3.77 (m, 8H), 4.76-4.81 (m, 2H), 5.13 (s, 2H), 6.42-6.44 (m, 1H), 6.70 (d, 1H, J= 8.1 Hz), 7.08-7.13 (m, 2H), 7.35-7.38 (m, 2H) 8.20 (s, 1H).

Example 2 – Susceptibility Testing

The NCCLS (National Committee for Clinical Laboratory Standards), method to determine MIC's of antimicrobial compounds is modified for high-throughput screening. All stocks of tested compounds are prepared in either water or in DMSO depending on solubility. At the highest concentration, DMSO content should not exceed 0.5%. Briefly, twenty 2-fold serial dilutions of test compounds from the highest concentration are made in a 384-well microtiter plate. Each well is inoculated with testing bacteria in broth to a final concentration of approximately 1-1.5X 10⁶ cells/ml. Bacterial growth is determined by the increase of optical density at 600 nm using a microplate reader (Tecan SpectraFluor Plus). The MIC is defined as the lowest concentration at which bacterial growth (equivalent to visible growth) was inhibited after 16 to 18 hours of incubation at the appropriate temperature required for the bacteria growth. Results for NB2046 are shown in Table 3 and Table 4.

Table 3

Organism	ATCC#	MIC (μ g/ml)	
		Exp. #1	Exp. #2
<i>S. aureus</i>	700260	\leq 0.125	\leq 0.125
<i>S. aureus</i>	700698	\leq 0.125	\leq 0.125
<i>S. aureus</i>	700699	16	8
<i>S. aureus</i>	13301	\leq 0.125	\leq 0.125
<i>S. aureus</i>	11632	\leq 0.125	\leq 0.125

Organism	ATCC#	MIC (μ g/ml)	
		Exp. #1	Exp. #2
<i>S. aureus</i>	14154	≤ 0.125	≤ 0.125
<i>S. aureus</i>	700787	≤ 0.125	≤ 0.125
<i>S. aureus</i>	700788	≤ 0.125	≤ 0.125
<i>S. aureus</i>	700789	≤ 0.125	≤ 0.125
<i>S. aureus</i>	43300	≤ 0.125	≤ 0.125
<i>S. aureus</i>	33591	≤ 0.125	≤ 0.125
<i>S. aureus</i>	33592	≤ 0.125	≤ 0.125
<i>S. aureus</i>	33593	≤ 0.125	≤ 0.125
<i>S. epidermidis</i>	27626	≤ 0.125	≤ 0.125
<i>S. epidermidis</i>	700565	2	2
<i>S. epidermidis</i>	700566	≤ 0.125	≤ 0.125
<i>S. epidermidis</i>	700578	0.5	0.25
<i>S. epidermidis</i>	700583	≤ 0.125	≤ 0.125
<i>K. pneumoniae</i>	51503	8	8
<i>K. pneumoniae</i>	51504	1	2
<i>K. pneumoniae</i>	700721	2	2
<i>E. aerogenes</i>	29751	2	1
<i>E. cloacae</i>	23355	0.5	0.5
<i>E. aerogenes</i>	29009	0.25	≤ 0.125
<i>E. aerogenes</i>	13048	1	1
<i>E. aerogenes</i>	35028	4	2
<i>M. catarrhalis</i>	49265	≤ 0.125	≤ 0.125
<i>M. catarrhalis</i>	51584	≤ 0.125	≤ 0.125
<i>M. catarrhalis</i>	43627	≤ 0.125	≤ 0.125
<i>M. catarrhalis</i>	43628	≤ 0.125	≤ 0.125

Table 4

Organism	ATCC #	MIC (μg/ml)	
		Exp. #1	Exp. #2
<i>E. coli</i>		16	16
<i>E. coli/Tem-1</i>		16	16
<i>MSSA</i>	700260	≤ 0.125	4
<i>MRSA</i>	700699	32	32
<i>MSSA</i>	33594	≤ 0.125	≤ 0.125
<i>MSSA</i>	11632	32	16
<i>E. faecalis</i>	49757	64	32
<i>E. faecalis</i>	700802	32	32
<i>E. fecium</i>			
<i>E. fecium</i>			
<i>E. aerogenes</i>	35028	32	16
<i>E. cloacae</i>	23355	16	1
<i>K. pneumoniae</i>	700721	4	8
<i>K. pneumoniae</i>	51503	4	8
<i>H. influenzae</i>	33533	64	≥ 64
<i>H. influenzae</i>	43334		
<i>P. aeruginosa</i>	21726	> 64	≥ 64
<i>P. aeruginosa</i>	29872	> 64	≥ 64

E. coli/TEM – *E. coli* expressing TEM-1 beta-lactamase; *MRSA* – Methicillin Resistant *S. Aureus*; *MSSA* – Methicillin Sensitive *S. Aureus*

Mammalian cells were treated with NB2046 as described above. The compound is not toxic to mammalian cells (IC_{50} of about 30 μ M) after 16 hours of exposure.

Using the assay provided above, the potency of NB2046 was compared to triclosan. Results are shown in Table 5.

Table 5

MSSA (ATCC ##)	NB2046 MIC, $\mu\text{g}/\text{ml}$	Triclosan MIC, $\mu\text{g}/\text{ml}$
700260	0.000031	0.000244
13301	0.000015	0.000488
11632	0.000977	0.001953
14154	0.000977	0.001953
33592	0.000488	0.003906
43300	0.000977	0.001953
700698	0.003906	0.003906
700699	≥ 4	≥ 4
700787	0.007813	0.001953
700788	0.062500	0.031250
700789	0.015630	0.015630
33591	0.015630	0.007813
33593	0.000488	0.000977

Example 3

5 In a separate experiment, cell-free reaction of PDF ECTA compounds has been studied using PDF purified from PDF-overexpressing *E.coli* following a procedure described in Ragusa S., et al. (2000) and Wei, et al. (2000b). NB3068 conversion was used as an example of a PDF ECTA reaction catalyzed by purified PDF. It was carried out in 50 mM HEPES buffer, pH 7.5 at room temperature. NB3068 concentrations were 10 in the range of 2 - 250 μM , and the concentration of the enzyme in the reaction mixture was 25 nM. The conversion was monitored by direct injection of the reaction mixture onto an HPLC column (Adsorbosphere HS, C18, 5 μm , 4.6 mm x 150 mm, Alltech). Both the decrease of NB3068 concentration and the increase of ciprofloxacin concentration were monitored, and initial rates of the reactions were calculated. Kinetic 15 parameters of the reaction were determined fitting the data to the Michaelis-Menten equation. The dependence of the rate of the reaction on the substrate concentration is given in Figure 2. From this dependence the following kinetic parameters of PDF-catalyzed NB3068 reaction were obtained: $k_{\text{cat}} = 2.07 \pm 0.14 \text{ s}^{-1}$, $K_m = 125 \pm 17 \mu\text{M}$, and $k_{\text{cat}}/K_m = 1.7 \times 10^4 \text{ M}^{-1}\text{s}^{-1}$.

Alternatively, a series of PDF ECTA compounds at a concentration of 20 - 100 μM in 50 mM HEPES buffer, pH 7.5 have been contacted with purified PDF at a concentration of 25 nM, and the consumption of the compound was followed. The consumption of the compound was fit to an exponential equation. Under the conditions 5 of the substrate concentration being less or comparable to K_m the exponential constant can be approximated as $(k_{\text{cat}}/K_m) \times [E]$. A relative catalytic efficiency parameter (k_{cat}/K_m) for a number of substrates has been determined; the k_{cat}/K_m value for NB3068 was assigned a value of 1 (see Table 6).

10 **Table 6 Properties of PDF ECTA compounds**

Ref. No.	Catalytic Efficiency	$t_{1/2} (\text{hrs})^*$			$t_{1/2} (\text{min})^*$	
		PBS	HEPES	Broth	Mouse Plasma	Human Plasma
NB3024	1.47	> 12 (81%)	> 12 (88%)	> 12 (82%)	n/d	n/d
NB3057	1.05	> 12 (82%)	> 12 (81%)	10	1.4	< 0.5
NB3068	1	> 12 (75%)	> 12 (70%)	> 12 (70%)	0.6	4.1
NB3103	0.84	> 12 (96%)	> 12 (95%)	> 12 (95%)	n/d	n/d

* $t_{1/2}$ – half-life (in parenthesis— percent of the compound remaining after 6 hours

** n/d – not determined

15

To confirm the role of PDF in catalyzing NB3068 transformation the rate of the reaction at different enzyme concentrations was determined (Figure 3 and 4). As can been seen the rate of the reaction is proportional to the enzyme concentration.

20 To further confirm the role of PDF NB3068 reaction catalyzed by purified PDF was studied in the presence of actinonin – PDF specific inhibitor. As can be seen from Figure 5 addition of actinonin to the reaction mixure slows down the reaction in dose dependent manner.

Example 4 –Stability

25 Stability of PDF ECTA compounds was determined in different media: PBS, pH 7.4 (Gibco Life Technologies), 50 mM HEPES buffer (Sigma) , pH 7.5, Mueller Hinton

broth (Becton Dickinson), mouse and human plasma (Sigma). Dependence of a compound concentration on time was fit to an exponential equation $c = c_0 \times \exp(-k \times t)$ where c is the running concentration of the compound, c_0 is its initial concentration and t is time. The compound half-life was determined as $t_{1/2} = 5 \cdot 0.693/k$.

Example 5 --Susceptibility testing

The NCCLS (National Committee for Clinical Laboratory Standards) method was used to determine MIC's of antimicrobial compounds. All stocks of tested 10 compounds were prepared in either water or DMSO based on the solubility. At the highest concentration of the tested compound DMSO content should not exceed 0.5 %. Briefly 2-fold serial dilutions of test compounds from the highest concentration were made in a 96-well microtiter plate. Each well was inoculated with testing bacteria in broth to a final concentration of approximately 5×10^5 CFU/ml. Bacterial growth was 15 monitored by the increase of optical density at 600 nm using a microplate reader (Tecan SpectraFluor Plus). The MIC was defined as the lowest concentration at which bacteria growth (equivalent to visible growth) was inhibited after 18 hours of incubation at 35°C. MIC values obtained for each compound are given in Table 7.

20

Table 7 MIC values for PDF ECTA compounds

Organisms	ATCC ##				
		NB3024	NB3057	NB3068	NB3103
<i>E.coli</i>	25922	16	0.0625	< 0.004	> 128
<i>E. faecalis</i>	29212	32	4	2	> 128
<i>S. aureus</i> (MS)	29213	8	0.125	2	> 128
<i>S. aureus</i> (MR)	33591	n/d *	0.5	n/d *	n/d *
<i>P. aeruginosa</i>	27853	128	2	0.5	> 128

* n/d – not determined

It is to be understood that while the invention has been described in conjunction 25 with the above embodiments, that the foregoing description and examples are intended to illustrate and not limit the scope of the invention. Other aspects, advantages and

modifications within the scope of the invention will be apparent to those skilled in the art to which the invention pertains.

References

5 Afpel, C. et al. (2000) *J. Med. Chem.* **43**:2324-2331.
Afpel et al. (2001a) *Anti. Agents and Chemo.* **45**(4):1053-1057.
Afpel et al. (2001b) *Anti. Agents and Chemo.* **45**(4):1058-1064.
Becker, A. et al. (1998) *Nat. Struct. Biol.* **5**(12): 1053-8.
10 Chan, M.K. et al. (1997) *Biochemistry* **36**(45):13904-9.
Chen, D.Z. et al. (2000) *Biochemistry* **39**(6):1256-62.
Clements, J.M. et al. (2001) *Anti. Agents and Chemo.* **45**(2):563-570.
de Groot, F.M.H. et al. (2000) *J. Med. Chem.* **43**:3093-3102.
Durand et al. (1999) *Arch. Bio. And Biophysics.* **367**(2): 297-302.
15 Giglione, C. et al. (2000a) *Mol. Microbiol.* **36**:1197205.
Giglione, C. et al. (2000b) *EMBO J.* **19**(21):5916-5929.
Hao, B. et al. (1999) *Biochemistry* **38**(15):4712-9.
Hu, Y.J. et al. (1998) *Bioorg Med Chem Lett.* **8**(18):2479-82.
Huntington, K.M. et al. (2000) *Biochemistry* **39**(15):4543-51.
20 Jayasekera, M.M. et al. (2000) *Arch. Biochm. Biophys.* **381**(2):313-316.
Meinnel, T. (1999) *Pathol. Biol.* **47**:780-783.
Meinnel, T. et al. (1993) *Biochimie.* **75**(12):1061-75. Review.
Nelson, D.L. et al. (2000) *Principles of Biochemistry.* 2000, ed. Lehninger,
Ragusa S., et al. (2000) *J.Mol.Biol.*, **280**, 551-523.
25 Rajagopalan, P.T. et al. (1997) *Biochemistry* **36**(45):13910-8.
Rajagopalan, P.T. et al. (1998) *Biol Chem.* **273**(35):22305-10.
Wei Y. et al. (1997) *Anal Biochem.* **250**(1):29-34.
Wei, Y. et al. (2000) *J Comb Chem.* **2**(6):650-7.
Wei, Y. et al. (2000b) *Bioorg Med Chem Lett.* **10**(10):1073-6.


30

CLAIMS

We claim:

1. A compound having the structure:

5



wherein R₁, R₂, R₄, and R₅ are independently the same or different and are
10 selected from the group consisting of hydrogen, a substituted or unsubstituted C₅-C₁₄ aryl group and a substituted or unsubstituted, saturated or unsaturated C₁-C₆ alkyl group;
wherein R₃ is selected from the group consisting of a substituted or
unsubstituted aryl group and a substituted or unsubstituted, saturated or unsaturated C₁-C₆ alkyl group and -CH₂-CH₂-X-CH₃, wherein X is selected from the group consisting
15 of -O-, -S-, -NH-, -NR₆-, and -CH₂-; where R₆ is a lower alkyl;
wherein A₁ and A₃ are independently the same or different and are selected from the group consisting of =O, =S, =NH, =N-OH, or =N-R₇, where R₇ is hydrogen or a C₁-C₆ alkyl;
wherein A₂, is absent or selected from the group consisting of =O, =S; =NH,
20 =N-OH, =N-R₈, or -C(R₉)(R₁₀)-, wherein R₈, R₉, and R₁₀ are independently the same or different and are selected from the group consisting of hydrogen or a C₁-C₆ alkyl;
wherein B₁ is selected from the group consisting of -O-, -S-, -NH- or -N(R₁₁)-, wherein R₁₁ is selected from the group consisting of hydrogen and a C₁-C₆ alkyl;
25 wherein B₂ is absent or is selected from the group consisting of -O-, -S-, -N(R₁₂)-, or -C(R₁₃)(R₁₄)-, where R₁₂, R₁₃, and R₁₄ are independently the same or different and are selected from the group consisting of hydrogen or a substituted or unsubstituted, saturated or unsaturated alkyl;
wherein the fragment -B₂-C(R₄)(R₅)-C(=A₃) - in its entirety is an naturally
30 occurring amino acid, analog, derivative or peptidomimetic thereof;

wherein B₃ is absent or is selected from the group consisting of -O-, -S-, or -NH-, or -N(R₁₅)-, wherein R₁₅ is selected from the group consisting of hydrogen and a C₁-C₆ alkyl;

5 wherein B₄ is absent or is selected from the group consisting of -O-, -S-, -N(R₆)-, and -C(R₁₆)(R₁₇)- and wherein R₁₆ and R₁₇ are independently the same or different and are selected from the group consisting of hydrogen or a substituted or unsubstituted, saturated or unsaturated alkyl;

 wherein a linker is absent or traceless;

10 and wherein a toxin is an agent that is toxic upon activation by an activating enzyme with the proviso that the toxin is not 5-fluorodeoxyuridine, or any derivative or analog thereof.

2. The compound of claim 1, wherein R₁ and R₂ are both hydrogen.

15 3. The compound of claim 2, wherein R₃ is -CH₂-CH₂-X-CH₃, wherein X is selected from the group consisting of oxygen, sulfur or methyl.

4. The compound of claim 3, wherein X is sulfur or oxygen.

20 5. The compound of claim 4, wherein A₁ and A₂ are both oxygen.

6. The compound of claim 5, wherein B₁ is -NH.

7. The compound of claim 1 linker is selected from the group consisting of
25 C₆H₄-CH₂- and -C₆H₄-CH₂-X₁-C(=X₂)- wherein X₁ and X₂ are independently the same or different are selected from the group consisting of -O-, -S- and -N(R_a), and where R_a is -hydrogen or a lower alkyl; and -(CH₂)_n-NR_b-(C=O)- wherein n = 2 or 3 and R_b is hydrogen or a lower alkyl.

30 8. The compound of claim 7, wherein B₄ is absent.

9. The compound of claim 8, wherein the toxin is selected from the group consisting of 2-mercaptopuridine-N-oxide, ciprofloxacin, norfloxacin, nitrogen mustard and the derivatives, analogues and pharmaceutically acceptable salts thereof.


5 10. The compound of claim 9, wherein B₂ is -NH, B₃ is -O-, R₄ is 2-methyl-propyl and R₅ is hydrogen.

11. The compound of claim 9, wherein the toxin is norfloxacin or a derivative, analog or pharmaceutically acceptable salt thereof.

10


12. The compound of claim 11, wherein the fragment -B₂-C(R₄)(R₅)-C(=A₃)- is proline, analog, derivative or peptidomimetic thereof.

15




14. A compound of claim 1, wherein the compound has the structure:


20



15. A compound of claim 1, wherein the compound has the structure:




5 16. A compound of claim 1, wherein the compound has the structure:



17. A compound of claim 1, wherein the compound has the structure:


10



18. A composition comprising the compound of claim 1 and a carrier.


19. The composition of claim 18, wherein the carrier is a pharmaceutically acceptable carrier.

20. A compound having the structure:



21. A compound having the structure:

5



22. A method for inhibiting the growth of a microorganism, comprising contacting the microorganism with an effective amount of the compound of claim 1.

10

23. The method of claim 22, wherein the microorganism expresses peptide deformylase.

15

24. A method for treating a subject comprising administering to the subject an effective amount of the compound of claim 1.

25. A method for identifying potential therapeutic agents, comprising:

20

(a) contacting a microorganism with a compound of claim 1 under conditions that favor the incorporation of the compound into the microorganism; and
(b) assaying for amount of proliferation of microorganism in comparison to an untreated sample of the microorganism.

26. The method of claim 25, wherein the microorganism expresses peptide deformylase.

25

THIS PAGE BLANK (USPTO)

1/5




Figure 1

THIS PAGE BLANK (series)

2/5




Figure 2

THIS PAGE BLANK (USPTO)

THIS PAGE BLANK

3/5




Figure 3

THIS PAGE BLANK (USPTO)

4/5




Figure 4

THIS PAGE BLANK (USPTO)

5/5




Figure 5

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)